P.R. Herzig & Co. Inc. raised its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 4.0% during the second quarter, according to its most recent filing with the SEC. The fund owned 33,645 shares of the biopharmaceutical company’s stock after buying an additional 1,301 shares during the period. Bristol-Myers Squibb makes up 3.6% of P.R. Herzig & Co. Inc.’s investment portfolio, making the stock its 9th largest position. P.R. Herzig & Co. Inc.’s holdings in Bristol-Myers Squibb were worth $1,875,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the stock. Franklin Resources Inc. raised its position in shares of Bristol-Myers Squibb by 21.8% in the fourth quarter. Franklin Resources Inc. now owns 1,890,564 shares of the biopharmaceutical company’s stock worth $110,495,000 after buying an additional 338,461 shares in the last quarter. Intellectus Partners LLC purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $227,000. Moloney Securities Asset Management LLC purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $1,736,000. Quest Investment Management Inc. OR raised its position in shares of Bristol-Myers Squibb by 5.1% in the fourth quarter. Quest Investment Management Inc. OR now owns 311,527 shares of the biopharmaceutical company’s stock worth $18,206,000 after buying an additional 14,978 shares in the last quarter. Finally, Bogle Investment Management L P DE purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $12,706,000. Institutional investors and hedge funds own 69.68% of the company’s stock.
Bristol-Myers Squibb Company (BMY) traded down 0.62% during trading on Friday, reaching $56.42. The company had a trading volume of 4,809,885 shares. The firm has a market capitalization of $92.52 billion, a P/E ratio of 20.61 and a beta of 1.17. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $60.45. The firm’s 50-day moving average price is $55.95 and its 200 day moving average price is $54.96. Bristol-Myers Squibb also was the target of unusually large options trading activity on Thursday. Stock investors purchased 781 put options on the company. This represents an increase of 117% compared to the average volume of 360 put options.
The company also recently declared a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th were paid a dividend of $0.39 per share. The ex-dividend date was Wednesday, July 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.76%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 56.73%.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/08/19/p-r-herzig-co-inc-has-1-88-million-stake-in-bristol-myers-squibb-company-bmy-updated-updated-updated.html.
Several analysts recently weighed in on the company. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Wednesday. BMO Capital Markets restated an “underperform” rating and set a $47.00 price objective (down from $51.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, July 26th. Leerink Swann lowered their price objective on Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a research report on Friday, July 28th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Finally, Jefferies Group LLC restated a “buy” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Bristol-Myers Squibb has an average rating of “Buy” and an average price target of $62.12.
In other news, Director Theodore R. Samuels II purchased 6,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the purchase, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.23% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
What are top analysts saying about Bristol-Myers Squibb Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb Company and related companies.